Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H3 antibody-drug conjugate YL201

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically conjugated to an as of yet undisclosed topoisomerase-1 inhibitor via a tumor protease-cleavable linker, with potential antineoplastic activity. Upon administration of anti-B7-H3 ADC YL201, the antibody moiety targets and binds to B7-H3-expressing tumor cells. Upon binding, internalization and linker cleavage, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing B7-H3. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation, and its overexpression plays a key role in tumor cell invasion and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC YL201
anti-B7-H3 ADC YL201
Code name:YL 201
YL-201
YL201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search